Vericel (VCEL) Income from Continuing Operations (2010 - 2026)
Vericel (VCEL) reported Income from Continuing Operations of 6838000.0 for Q1 2026, up 41.85% on a YoY basis from 4820457.98 in Q1 2025, and down 128.33% sequentially from 24138000.0 in Q4 2025.
Vericel (VCEL) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Vericel (VCEL) has 17 years of Income from Continuing Operations data on file, last reported at 6838000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 41.85% year-over-year to 6838000.0; the trailing twelve-month figure through Mar 2026 stood at 20936000.0 (up 946.8% YoY), and the FY2025 full-year result was 16518000.0, up 59.41% from the prior year.
- Income from Continuing Operations retreated to 6838000.0 in Q1 2026, from 24138000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 24138000.0 in Q4 2025 to a low of 55882000.0 in Q2 2023.
- A 5-year average of 3094823.53 and a median of 4327000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations slumped 523.47% in 2023 and surged 614.21% in 2025, its largest moves.
- Tracing VCEL's Income from Continuing Operations over 5 years: stood at 5922000.0 in 2022, then surged by 119.4% to 12993000.0 in 2023, then soared by 52.44% to 19807000.0 in 2024, then increased by 21.87% to 24138000.0 in 2025, then tumbled by 128.33% to 6838000.0 in 2026.
- Business Quant data shows VCEL's Income from Continuing Operations at 6838000.0 in Q1 2026, 24138000.0 in Q4 2025, and 4633000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Vericel | 2.30 Bn | 2.15 Bn | 49.27 Mn | -6.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.84 Mn |
| Dec 31, 2025 | 24.14 Mn |
| Sep 30, 2025 | 4.63 Mn |
| Jun 30, 2025 | -997,000.00 |
| Mar 31, 2025 | -11.76 Mn |
| Dec 31, 2024 | 19.81 Mn |
| Sep 30, 2024 | -901,000.00 |
| Jun 30, 2024 | -5.15 Mn |
| Mar 31, 2024 | -4.33 Mn |
| Dec 31, 2023 | 12.99 Mn |
| Sep 30, 2023 | -3.66 Mn |
| Jun 30, 2023 | -55.88 Mn |
| Mar 31, 2023 | -7.96 Mn |
| Dec 31, 2022 | 5.92 Mn |
| Sep 30, 2022 | -6.58 Mn |
| Jun 30, 2022 | -8.96 Mn |
| Mar 31, 2022 | -7.09 Mn |
| Dec 31, 2021 | 4.54 Mn |
| Sep 30, 2021 | -4.93 Mn |
| Jun 30, 2021 | -3.79 Mn |